Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 6/20 | 0.49 |
| ▸ | JAK3 | P52333 | 6/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13268027 | 0.89 | BRD4 (0.58) | BRD4JAK2JAK3FLT3JAK1 | |
| SCHEMBL13268014 | 0.88 | BRD4 (0.55) | BRD4TNK2JAK2JAK3FLT3 | |
| SCHEMBL13268177 | 0.88 | JAK1 (0.57) | BRD4JAK2JAK3FLT3JAK1 | |
| SCHEMBL12854451 | 0.86 | BRD4 (0.52) | BRD4TNK2JAK2JAK3FLT3 | |
| SCHEMBL13268122 | 0.85 | BRD4 (0.51) | BRD4TNK2JAK2JAK3FLT3 | |
| SCHEMBL12854456 | 0.85 | BRD4 (0.50) | BRD4TNK2JAK2JAK3FLT3 | |
| SCHEMBL13268246 | 0.84 | BRD4 (0.53) | BRD4TNK2JAK2JAK3FLT3 | |
| SCHEMBL14553233 | 0.84 | JAK1 (0.43) | BRD4JAK2JAK3FLT3JAK1 | |
| SCHEMBL13268041 | 0.82 | BRD4 (0.53) | BRD4JAK2JAK3FLT3JAK1 | |
| SCHEMBL14482288 | 0.82 | BRD4 (0.59) | BRD4TNK2JAK2JAK3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 758/4885TNK2 39/4885JAK2 854/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 789/4885TNK2 68/4885JAK2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.